Mitomycine Substipharm (Mitomycin)

Mitomycin is activated inside low‑oxygen tumor cells where it is reduced to a reactive alkylating agent. This agent creates covalent cross‑links between DNA strands, preventing DNA replication and transcription. The resulting DNA damage triggers apoptosis, selectively targeting rapidly dividing cancer cells while sparing most normal tissues.

The dose of Mitomycine Substipharm is individualized by the prescribing oncologist based on the specific cancer type, treatment protocol, patient weight, renal function, and prior therapy. Clinicians determine the appropriate amount, infusion rate, and schedule in accordance with established clinical guidelines and local regulatory requirements.

Safety data for mitomycin during pregnancy and lactation are limited, and the drug is classified as contraindicated for use in pregnant or breastfeeding women. Potential risks to the fetus or infant are unknown, so clinicians generally avoid prescribing it to these populations unless the therapeutic benefit clearly outweighs the risk.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any necessary import documentation.

Compared with other antineoplastic antibiotics such as doxorubicin, mitomycin has a distinct mechanism that relies on DNA cross‑linking under hypoxic conditions, making it especially useful for bladder cancer administered intravesically. While both classes cause myelosuppression, mitomycin’s pulmonary toxicity profile differs, and its efficacy in certain solid tumors may be enhanced when combined with platinum‑based regimens.

Mitomycine Substipharm must be stored at 2‑8 °C in a refrigerator. The vial should be kept in its original packaging, protected from light, and should never be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer.

The product is supplied as an injectable solution for intravenous infusion or intravesical instillation. For systemic therapy, it is diluted in an appropriate carrier fluid and infused over a prescribed period under clinical supervision. For bladder cancer, the solution is directly instilled into the bladder via a catheter and retained for a defined dwell time as directed by the treating physician.

The most serious adverse events include severe myelosuppression leading to life‑threatening infections or bleeding, pulmonary toxicity such as interstitial pneumonitis or fibrosis, acute renal impairment, and rare but severe hypersensitivity reactions (anaphylaxis). Patients should be monitored closely for signs of infection, respiratory distress, and renal function changes throughout treatment.

Mitomycine Substipharm is contraindicated in individuals with known hypersensitivity to mitomycin or any component of the formulation, in pregnant or breastfeeding women, and in patients with severe renal impairment where dose adjustment is not feasible. Caution is also advised for patients with pre‑existing pulmonary disease or those receiving other myelosuppressive therapies.